GleamWall
中文EN

BIOA BioAge Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1709941 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.3%
TTM net income YoY-42.2%
TTM EPS YoY-118.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,401.8%
Net margin-1,253.6%
FCF margin-1,197.8%
EBITDA margin—

Returns

ROE-34.6%
ROA-32.0%
ROIC (approx.)-52.9%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets5.8%
Debt / equity0.00x
Current ratio15.51x
Interest coverage-913.20x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$298,000$2.45M$2.77M$3.08M$2.05M$2.41M$1.45M$0
R&D expense$30.23M$24.36M$20.41M$24.50M$18.51M$19.84M$11.11M$19.23M
SG&A expense$7.48M$7.42M$7.74M$7.00M$6.68M$7.34M$6.79M$6.14M
Operating income-$37.41M-$29.33M-$25.38M-$28.42M-$23.14M-$24.77M-$16.45M-$25.36M
Interest expense$0$1,000$39,000$92,000$149,000$201,000$255,000$319,000
Net income-$33.50M-$26.10M-$22.25M-$25.94M-$20.17M-$21.56M-$12.93M-$21.13M
EBITDA-$37.31M——-$28.32M-$23.14M——-$25.26M
EPS (basic)-0.73-0.58-0.52—-0.56-0.60-0.36—
EPS (diluted)-0.73-0.58-0.52—-0.56-0.60-0.36—
Weighted avg. shares (diluted)45.91M44.84M42.48M—35.85M35.85M35.85M—
Balance sheet
Cash & equivalents$52.67M$73.96M$241.78M$188.89M$215.57M$220.33M$257.49M$354.35M
Short-term investments$230.97M$244.78M$141.42M$92.21M$70.20M$76.97M$63.03M$0
Receivables$565,000$625,000$709,000$769,000$515,000$603,000$361,000$0
Current assets$295.05M$330.31M$391.86M$286.79M$290.83M$301.70M$324.81M$357.10M
PP&E, net$1.13M$1.21M$1.11M$963,000$973,000$974,000$929,000$591,000
Total assets$367.65M$396.93M$397.65M$294.89M$305.09M$322.15M$343.84M$358.23M
Current liabilities$19.03M$19.22M$15.83M$20.14M$24.49M$22.84M$23.74M$27.77M
Short-term debt$0$0$1.16M$2.65M$4.13M$5.60M$6.00M$6.00M
Long-term debt———$0$0$0$1.06M$2.50M
Total debt———$2.65M$4.13M$5.60M$7.06M$8.50M
Total liabilities$21.20M$22.02M$18.53M$22.84M$27.63M$27.37M$30.67M$35.11M
Shareholders' equity$346.45M$374.91M$379.12M$272.05M$277.46M$294.78M$313.17M$323.13M
Net debt———-$186.24M-$211.45M-$214.73M-$250.43M-$345.85M
Shares outstanding45.95M45.78M44.39M37.39M35.85M35.85M35.85M35.85M
Cash flow statement
Operating cash flow-$30.96M-$19.26M-$24.05M-$28.25M-$16.04M-$19.97M-$17.36M-$5.14M
Capital expenditure$18,000$328,000$26,000$112,000$22,000$159,000$426,000$26,000
Free cash flow-$30.98M-$19.59M-$24.07M-$28.36M-$16.07M-$20.13M-$17.79M-$5.16M
Investing cash flow$7.54M-$164.51M-$46.75M-$14.43M$12.84M-$15.64M-$77.99M-$26,000
Financing cash flow$2.08M$15.97M$123.72M$16.01M-$1.54M-$1.50M-$1.50M$24.90M
Depreciation & amortization$100,000——$100,000$0——$100,000
Stock-based compensation$4.64M$4.27M$4.26M$2.72M$2.79M$3.23M$2.95M$2.72M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.